views
According to the report, the global iron deficiency anemia treatment market was valued at US$ 9.2 Bn in 2019 and is projected to expand at a CAGR of ~9% from 2020 to 2030. Iron deficiency is the most common cause of anemia globally. Rise in prevalence of chronic kidney diseases, increase in risk of hemodilution in pregnant women, and surge in iron deficiency in individuals are the major factors anticipated to drive the global iron deficiency anemia treatment market during the forecast period. North America held a major share of the global iron deficiency anemia treatment market in 2019, due to large population suffering from iron deficiency, higher awareness about iron deficiency anemia, and increase in focus on new product launches by industry players. The iron deficiency anemia treatment market in Asia Pacific is expected to expand at a high CAGR of 9.5% from 2020 to 2030 due to increase in the number of geriatric patients suffering from iron deficiency and chronic kidney diseases.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81221
Rise in Prevalence of Iron Deficiency Anemia to Drive Market
Increase in prevalence of iron deficiency anemia across the globe is likely to drive the global iron deficiency anemia treatment market during the forecast period. Iron deficiency anemia is a common type of nutritional anemia and considered a major public health problem globally. It results in low level of hemoglobin in the blood. According to the WHO, anemia affects 1,500 million to 1,740 million people globally, with 50% of all anemia attributed to iron deficiency. Moreover, a study conducted for national primary care database in Germany, Belgium, Spain, and Italy, states that the annual incidence rate of iron deficiency anemia ranged from 7.2 to 13.9 per 1,000 person-years.
Ferrous Sulfate to Dominate Global Market
In terms of drug type, the global iron deficiency anemia treatment market has been classified into ferrous sulfate, ferrous gluconate, ferrous fumerate, ferric hydroxide, sodium ferric gluconate, iron carbohydrates, and others. The ferrous sulfate segment dominated the global iron deficiency anemia treatment market in 2019 and the trend is projected to continue during the forecast period. The availability in generic form, low cost, and higher preference in the treatment of iron deficiency anemia is anticipated to boost the ferrous sulfate segment.
Request COVID Analysis on Iron Deficiency Anemia Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81221
Tablets to be Preferred Dosage Form
In terms of dosage form, the global iron deficiency anemia treatment market has been categorized into tablets, capsules, and liquid. The tablets segment held major share of the global iron deficiency anemia treatment market in 2019. Tablet is the most stable, inexpensive, and widely available dosage form for the treatment of iron deficiency anemia. High acceptance of tablet dosage form in hospital inpatient and outpatient settings, rise in disposable income, and increase in government support are likely to drive the segment in the near future.
Hospital Pharmacies to Remain Major Distribution Channel
Based on distribution channel, the global iron deficiency anemia treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2019, owing to benefits such as individualized medication plan and quality medication and increase in the number of hospital pharmacies in developing countries.
Request Customization on Iron Deficiency Anemia Treatment Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=81221
North America to Dominate Global Market; Asia Pacific to Offer Significant Opportunities
In terms of region, the global iron deficiency anemia treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a leading share of the global iron deficiency anemia treatment market during the forecast period. Rise in prevalence of chronic kidney diseases and increase in patient base of iron deficient women in North America leading to a surge in demand for iron deficiency anemia treatment are major factors driving the market in the region. According to the CDC, in 2019, 15% of the U.S. adults i.e., 37 million people are anticipated to have had chronic kidney disease. Moreover, 15% women are suffering from CKD compared to 12% men. Furthermore, it is more common in people aged 65 years or older in the country. The market in Europe is expected to expand at a high CAGR in the near future, owing to the presence of local as well as global players and rise in demand for iron deficiency anemia treatment in the region.
The iron deficiency anemia treatment market in Asia Pacific is likely to grow at a rapid pace in the near future. India and China are anticipated to be lucrative markets for iron deficiency anemia treatment during the forecast period. Presence of large geriatric patient population with iron deficiency and increase in healthcare expenditure in these countries are projected to propel the market in Asia Pacific over the next few years.
Growth Strategies of Key Players
Key players operating in the global iron deficiency anemia treatment market are AdvaCare Pharma, Akorn, Sun Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Rockwell Medical, Inc., Vifor Pharma Management Ltd., Shield Therapeutics, AMAG Pharmaceuticals, and Pharmacosmos A/S. These companies engage in research & development to develop novel products in order to expand product offerings and customer base. In March 2020, Rockwell Medical, Inc. received the U.S. FDA approval for its intravenous formulation of Triferic, Triferic AVNU. This approval enabled the company to expand its product portfolio and strengthen its position in the global iron deficiency anemia treatment market.
Buy Iron Deficiency Anemia Treatment Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=81221<ype=S
Global Iron Deficiency Anemia Treatment Market: Segmentation
· Iron Deficiency Anemia Treatment Market, by Drug Type
o Ferrous Sulfate
o Ferrous Gluconate
o Ferrous Fumerate
o Ferric Hydroxide
o Sodium Ferric Gluconate
o Iron Carbohydrates
o Others
· Iron Deficiency Anemia Treatment Market, by Dosage Form
o Tablets
o Capsules
o Liquid
· Iron Deficiency Anemia Treatment Market, by Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
· Iron Deficiency Anemia Treatment Market, by Region
o North America
o U.S.
o Canada
o Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
o Asia Pacific
o China
o India
o Japan
o Australia & New Zealand
o Rest of Asia Pacific
o Latin America
o Brazil
o Mexico
o Rest of Latin America
o Middle East & Africa
o GCC Countries
o South Africa
o Rest of Middle East & Africa
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com